StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
May 13, 2024 12:31 PM
Stifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $22.00 (from $19.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)
May 14, 2024 8:47 AM
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 1c, provides guidance
May 13, 2024 7:25 AM
Form 10-Q Fulcrum Therapeutics, For: Mar 31
May 13, 2024 7:16 AM
Form 8-K Fulcrum Therapeutics, For: May 11
May 13, 2024 7:05 AM
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024 7:00 AM
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024 6:00 AM
Form 4 Fulcrum Therapeutics, For: May 07 Filed by: Tourangeau Greg
May 9, 2024 4:12 PM
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 9, 2024 8:00 AM
